Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

No longer available 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 15Neoplasm, Residual 2Myelodysplastic Syndromes 2Mastocytosis, Systemic 2Leukemia, Mast-Cell 2Leukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Congenital Abnormalities 1Aggression 1

Interventions

avapritinib 5midostaurin 2masitinib 2ripretinib 1nilotinib 1Interviews as Topic 1Imatinib Mesylate 1Azacitidine 1AK002 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Mastocytosis, Systemic × midostaurin × Clear all
NCT05219266 2024-06-28

Managed Access Programs for PKC412, Midostaurin

Novartis

No longer available
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed
116 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡